TipRanks
ImmuPharma PLC (DE:25I)
FRANKFURT:25I
Germany Market
25I
ImmuPharma
RESEARCH TOOLSreports

ImmuPharma (25I) Income Statement

0 Followers

ImmuPharma Income Statement

Last quarter (Q2 2026), ImmuPharma's total revenue was £0.00, a decrease of ― from the same quarter last year. In Q2, ImmuPharma's net income was £-4.70M. See ImmuPharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
£ 0.00£ 0.00£ 0.00£ 0.00£ 118.35K
Gross Profit
£ -35.30K£ -63.88K£ -37.61K£ -118.00K£ 118.35K
Operating Expenses
£ 2.51M£ 2.67M£ 3.06M£ 2.91M£ 6.71M
Depreciation and Amortization
£ 35.30K£ 63.88K£ 37.61K£ 117.56K£ 114.12K
EBITDA
£ -2.51M£ -2.61M£ -3.02M£ -2.91M£ -8.70M
Operating Income
£ -2.54M£ -2.68M£ -3.06M£ -3.03M£ -6.59M
Other Income/Expenses
£ 370.56K£ -104.00K£ -356.00K£ -1.43M£ -2.35M
Pretax Income
£ -2.17M£ -2.78M£ -3.42M£ -4.46M£ -8.94M
Net Income
£ -1.81M£ -2.48M£ -2.92M£ -3.81M£ -8.17M
Per Share Metrics
Basic EPS
£ >-0.01£ >-0.01£ >-0.01£ -0.01£ -0.03
Diluted EPS
£ >-0.01£ >-0.01£ >-0.01£ -0.01£ -0.03
Weighted Average Shares Outstanding
 490.59M 413.92M 360.71M 302.91M 251.16M
Weighted Average Shares Outstanding (Diluted)
 490.59M 416.44M 362.00M 302.91M 251.16M
Currency in GBP

ImmuPharma Earnings and Revenue History